Macroscopic modeling of singlet oxygen ( 1 O 2 ) is of particular interest because it is the major cytotoxic agent causing biological effects for type II photosensitizers during PDT. We have developed a macroscopic model to calculate reacted singlet oxygen concentration ([1O2] rx for PDT. An in-vivo RIF tumor mouse model is used to correlate the necrosis depth to the calculation based on explicit PDT dosimetry of light fluence distribution, tissue optical properties, and photosensitizer concentrations. Inputs to the model include 4 photosensitizer specific photochemical parameters along with the apparent singlet oxygen threshold concentration. Photosensitizer specific model parameters are determined for several type II photosensitizers (Photofrin, BPD, and HPPH). The singlet oxygen threshold concentration is approximately 0.41 -0.56 mM for all three photosensitizers studied, assuming that the fraction of singlet oxygen generated that interacts with the cell is (f = 1). In comparison, value derived from other in-vivo mice studies is 0.4 mM for mTHPC. However, the singlet oxygen threshold doses were reported to be 7.9 and 12.1 mM for a multicell in-vitro EMT6/Ro spheroid model for mTHPC and Photofrin PDT, respectively. The sensitivity of threshold singlet oxygen dose for our experiment is examined. The possible influence of vascular vs. apoptotic cell killing mechanism on the singlet oxygen threshold dose is discussed using the BPD with different drug-light intervals 3 hrs vs. 15 min. The observed discrepancies between different experiments warrant further investigation to explain the cause of the difference.
INTRODUCTION
Photodynamic therapy (PDT) is an anti-cancer treatment modality based on the interaction of light, a photosensitizing drug, and oxygen. 1 PDT has been approved by the US Food and Drug Administration for the treatment of microinvasive lung cancer, obstructing lung cancer, and obstructing esophageal cancer and Barrett's esophagus with high grade dysplasia, as well as for age-related macular degeneration and actinic keratosis. 2 Photodynamic therapy is inherently a complex process in which the PS, light and oxygen vary dynamically and interdependently on timescales specific to an individual treatment condition. Thus, the distribution of light is determined by the light source characteristics and the effective tissue optical absorption and scattering at the treatment wavelength. The effective absorption is affected by the local concentration of PS and the concentration and oxygenation status of the blood. The oxygen distribution is altered by photodynamic consumption and any PDT-induced changes in blood flow 3 . The effective PS concentration and distribution may change due to photobleaching. These effects make accurate PDT dosimetry extremely challenging, but this is critical to achieve optimal efficacy and safety, particularly when there is curative intent, as demonstrated in several tumor sites 4, 5 . For type-II PSs, excited-state singlet oxygen ( 1 O 2 ), the major cytotoxic species causing biological effects, is generated upon the absorption of light by the PS in the presence of ground-state molecular oxygen ( 3 O 2 ). Thus, direct measurement of 1 O 2 constitutes the ultimate PDT dosimetry method to correlate with PDT outcome. The production of singlet oxygen that has damaged the tissue can be expressed as:
where f depends on the localization of the photosensitizer at the cell level and thus depends on the photosensitizer and tissue types, the singlet oxygen quantum yield η gives the number of singlet oxygen molecules produced per an absorbed 
METHOD
Most photosensitizers available for PDT utilize Type II photodynamic processes, i.e., the photodynamic effect is achieved through the production of singlet oxygen. 7, 8 The energy level diagram shown in Fig. 1 summarizes the underlying physical processes involved in type-II PDT. The process begins with the absorption of a photon by photosensitizer in its ground state, promoting it to an excited state. The photosensitizer molecule can return to its ground state by emission of a fluorescence photon, which can be used for fluorescence detection. Alternatively, the molecule may convert to a triplet state, a process known as intersystem crossing (ISC). A high intersystem-crossing yield is an essential feature of a good Type II photosensitizer. Once in its triplet state, the molecule may undergo a collisional energy transfer with ground state molecular oxygen (type II) or with the substrate (type I). In type II interaction, the photosensitzer returns to its ground state, and oxygen is promoted from its ground state (a triplet state) to its excited (singlet) state. Since the photosensitizer is not consumed in this process, the same photosensitizer molecule may create many singlet oxygen molecules.
Once the singlet oxygen is created, it reacts almost immediately with cellular targets in its immediate vicinity. The majorities of these reactions are irreversible, and lead to consumption of oxygen. This consumption of oxygen is efficient enough to cause measurable decreases in tissue oxygenation when the incident light intensity is high enough. In addition to its reactions with cellular targets, singlet oxygen may react with the photosensitizer itself. This leads to its irreversible destruction (photobleaching). Photobleaching can decrease the effectiveness of PDT by reducing the photosensitizer concentration, however it can also be useful for dosimetry. 9 Because of its high reactivity, singlet oxygen has a very short lifetime in tissue. However, a small fraction of the singlet oxygen produced may return to its ground state via emission of a phosphorescence photon, which can be detected optically. 10, 11 We use k i (i = 0, 1, …, 7) to designate the reaction rate. The definitions associated with the reaction rates are summarized in 
BPD: 11.9 * HPPH: 11.9 * * These photochemical parameters are currently not available in the literature; we have taken the value of Photofrin. **The parameter ξ are obtained using the study of Georgakoudi et al. 19 and Mitra et al. 18 from tumor spheroid studies, where ξ equals to β PDT /[S 0 ], β PDT is a proportional constant between photochemical oxygen consumption rate and the fluence rate. 18 ξ is either calculated according to the β PDT value from the literature 18, 19, 22 or based on the current mouse studies (fitted value).
Macroscopic kinetics rate equations
We adopted the rate equation approach first proposed by Foster et al 23 
Here the reacted singlet oxygen concentration is defined as
and is consistent with the definition in Eq. 1. Using Eq. 5, we can recover Eq. 1 with η =
. Parameters for the rate equations are listed in Table 1 for several photosensitizers. The corresponding expressions for the instantaneous singlet oxygen, singlet, and triplet states of PS are:
The rate equations are implemented in the Matlab code. The calculation time is in seconds for the rate equation alone and minutes for the time and spatially coupled differential equations.
Mice necrosis experiment to determine singlet oxygen threshold dose
We have performed necrosis studies in mice to determine the necrosis generated by three photosensitizers (Photofrin, BPD, and HPPH) in RIF tumor model. Table 2 summarizes the conditions for the PDT. RIF tumor was grown on the shoulder. PDT was performed using 1-cm long cylindrical diffusing fiber (CDF) to deliver light with various fluence rate and total treatment time. 21 The mice were sacrificed at 24 hours after PDT and the tumor is resected perpendicular to the CDF. Experimental setup and an example of H&E staining of RIF tumor resection were shown in Fig. 2 . Table 1 for BPD. The corresponding source strength, total energy released per unit length, and initial photosensitizer concentration for each group of 3 mice are shown in Table 3 Table 1 for HPPH. The corresponding source strength, total energy released per unit length, and initial photosensitizer concentration for each group of 3 mice are shown in Table 4 . The symbol with error bar indicates the PDT-induced necrotic radius with standard deviation for each mouse. (b) PDT-induced necrotic radius predicted vs. measured for mice shown in figure (a).
RESULTS AND DISCUSSION

Macroscopic modeling of singlet oxygen threshold dose
The number of mice used for each photosensitizer is 16, 18, and 24 for Photofrin, BPD, and HPPH, respectively. The treatment conditions are listed in Tables 3 -4 for BPD and HPPH, respectively. The treatment condition for Photofrin is included in the legend of Fig. 3 . Table 5 summarizes the singlet oxygen threshold dose based on fit shown in Figs. 3-5. For comparison, singlet oxygen threshold dose for PDT from other studies are included. Clearly there is a different of singlet oxygen threshold dose between in-vivo results measured in mouse (0.4 -0.6 mM) and that from spheroid measurement (8 -12 mM). Our study is consistent with other in-vivo mice studies. However, the in-vivo results are at least 10 times smaller than those observed in spheroid, indicating possible other effect in PDT damage in-vivo. 25 We have also included threshold dose obtained for BPD with DLI of 15 min (BPD 1mg/kg, 690 nm) where vascular effect is predominant. This lower singlet oxygen threshold dose of 0.08 mM 26 is to be expected, given the PS concentration (~0.15 µM) in tissue for BPD with 15 min DLI is much lower than that (~0.6 µM) for BPD with apoptosis effect to be dominant for 3 hr DLI. Radius (mm) 5 
Uncertainty in singlet oxygen threshold dose determination
To examine the error in our experiments to determine the singlet oxygen threshold dose, we have plotted all the individual measurement between the reacted singlet oxygen and necrosis radius. Figure 6 shows all the necrosis results for HPPH and BPD while Fig. 3a shows that for Photofrin. We concluded that the maximum spreads of singlet oxygen dose are 0.2 -0.95 mM for Photofrin, 0.1 -0.73 mM for BPD, and 0.2 -0.65 mM for HPPH. The upper limit of singlet oxygen threshold dose in vivo is thus 1 mM from our study.
(a) (b) Figure 6 : [ 1 O 2 ] rx profiles for 24 mice using the model parameters (ξ, σ, β, g) in Table 1 for (a) HPPH and (b) BPD.
Theoretical consideration of singlet oxygen threshold dose
One can write down the relationship between the singlet oxygen and the acceptors as:
(8) The solution of this equation is thus
Thus, the threshold value of cumulative singlet oxygen production for sufficient cellular target killing is k 7 24 This value is an order of magnitude higher than our experimental value determined in-vivo (~ 0.5 mM), but is consistent (to within a factor of 2) with the value determined in the spheroid model (~10 mM), see Table 5 .
Using the direct measurement of number of RIF tumor cells in-vivo, 5 x 10 8 /cm 3 , the measured singlet oxygen threshold dose (0.5 mM) can then be converted to number of singlet oxygen required to kill each cell to 1/e: 8.7×10
7 (= 0.5 (mM)/6.91 x 10 -3 (M/mM) x 6.022x10 23 (1/mole)/ 1000 (L/cm 3 )/5 x 10 8 ), where 6.91 (=3*ln10) is a factor to convert the cell killing from 10 -3 to 1/e, assuming the cell killing is following Eq. 9. In comparison, in-vitro measurement in MatLyLu cells using mTHPC gives this value as 9 ×10 8 molecules of singlet oxygen per cell to reduce the surviving fraction by 1/e. 15 The in-vivo singlet oxygen threshold dose (8.7×10 7 /cell) is again about 10 times smaller than that determined in-vitro (9×10 8 /cell).
In conclusion, the singlet oxygen threshold dose measured in vivo is approximately 0.5 mM to produce necrosis or 8.7×10 7 molecules of singlet oxygen per cell to reduce the surviving fraction by 1/e from our RIF tumor model. This value is at least an order of magnitude smaller than either Spheroid model (~7.9 mM) to produce necrosis or in-vitro model of Mat-Lylu cells 9×10 8 molecules of singlet oxygen per cell to reduce the surviving fraction by 1/e using mTHPC.
Conclusions
We have shown that using a set of rate equations and fitting the data to the necrosis radius in a RIF mouse model, we can determine the threshold dose of singlet oxygen in-vivo. Preliminary study has shown that singlet oxygen threshold dose is in the range of 0.41 -0.56 mM for three photosensitizers studied, Photofrin, BPD, and HPPH. This value is about 10 times smaller than that determined in-vitro. We thus come to a conclusion that PDT is more potent in vivo than that invitro, as pointed out by Wang et al 25 as well.
